SELLAS Life Sciences (SLS) Invested Capital (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Invested Capital data on file, last reported at $107.4 million in Q1 2026.

• Invested Capital for Q1 2026 came in at $107.4 million, up 286.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $107.4 million (up 286.94% YoY), and the FY2025 annual result was $70.9 million, up 648.77% from the prior year.
• Invested Capital advanced to $107.4 million in Q1 2026 per SLS's latest filing, from $70.9 million in the prior quarter.
• Over five years, Invested Capital peaked at $107.4 million in Q1 2026 and troughed at -$8.0 million in Q4 2023.
• A 5-year average of $21.3 million and a median of $12.6 million in 2022 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2023 and 2025: Invested Capital tumbled 264.42% in 2023, then jumped 797.67% in 2025.
• A 5-year view of Invested Capital shows it stood at $4.9 million in 2022, then plunged by 264.42% to -$8.0 million in 2023, then soared by 218.67% to $9.5 million in 2024, then surged by 648.77% to $70.9 million in 2025, then surged by 51.56% to $107.4 million in 2026.
• Business Quant data shows SLS's Invested Capital at $107.4 million in Q1 2026, $70.9 million in Q4 2025, and $45.6 million in Q3 2025.